Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
19.82
+0.05 (0.25%)
At close: Feb 27, 2026
0.25%
Market Cap 32.35B
Revenue (ttm) 24.18B
Net Income (ttm) 1.43B
Shares Out 1.63B
EPS (ttm) 0.87
PE Ratio 22.68
Forward PE 13.93
Dividend 0.47 (2.37%)
Ex-Dividend Date Aug 19, 2025
Volume 11,560,840
Average Volume 20,197,932
Open 19.75
Previous Close 19.77
Day's Range 19.72 - 19.90
52-Week Range 16.73 - 23.66
Beta 0.51
RSI 67.86
Earnings Date Mar 31, 2026

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec... [Read more]

Sector Healthcare
Founded 1988
Employees 17,650
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2024, SHA:600079's revenue was 25.44 billion, an increase of 3.71% compared to the previous year's 24.52 billion. Earnings were 1.33 billion, a decrease of -37.70%.

Financial Statements

News

There is no news available yet.